{"nctId":"NCT01539538","briefTitle":"A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain","startDateStruct":{"date":"2012-04"},"conditions":["Post-Operative Pain"],"count":357,"armGroups":[{"label":"Sufentanil NanoTab PCA System/15 mcg","type":"EXPERIMENTAL","interventionNames":["Drug: Sufentanil NanoTab PCA System/15 mcg"]},{"label":"morphine IV PCA","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: morphine IV PCA"]}],"interventions":[{"name":"Sufentanil NanoTab PCA System/15 mcg","otherNames":["Zalviso™"]},{"name":"morphine IV PCA","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients who are 18 years or older\n* Patients who are scheduled to undergo an open abdominal surgery (including laparoscopic-assisted), total knee or total hip replacement surgery under general anesthesia or spinal anesthesia that does not include intrathecal opioids during the operation.\n* Post-surgical patients who have been admitted to the PACU and are expected to remain hospitalized and to have acute post-operative pain requiring parenteral opioids for at least 48 hours after surgery.\n\nExclusion Criteria:\n\n* Patients who have taken an opioid for more than 30 consecutive days, at a daily dose of more than 15 mg of morphine (or equivalent), within the past 3 months prior to surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg hydrocodone per tablet).\n* Patients with an allergy or hypersensitivity to opioids\n* Female patients who are pregnant or breast-feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Patient Global Satisfaction","description":"Proportion of patients responding good or excellent at 48-hour global assessment of method of pain control","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.5","spread":null},{"groupId":"OG001","value":"65.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":177},"commonTop":["nausea","vomiting","constipation","oxygen saturation decreased","hypotension"]}}}